Zalgen Labs, LLC
Zalgen Labs, LLC (Zalgen) was founded in 2011 and commenced operations in August 2013 at the Germantown Innovation Center, established by Maryland Economic Development Corporation, a public instrumentality of the state of Maryland. Zalgen specializes in the design and production of critical biological molecules for development and commercialization of reliable, rapid, and affordable diagnostics; novel, non-live, safer vaccines; effective immunotherapeutic platforms targeting neglected human diseases. Zalgen’s founders have successfully developed first-to-field-use rapid diagnostic tests for Lassa fever and Ebola virus disease, aided by a consortium of academic, institutional, and biotechnology partners comprising the VHFC. These are revolutionizing the understanding of epidemiological, immunological, and basic research notions of Lassa fever, thus contributing to dramatic improvements in the management and successful outcomes of this viral disease.
The lack of effective therapeutics for many neglected diseases, including Lassa fever, led Zalgen’s founders and VHFC partners to initiate development of first-in-class immunotherapeutic against Lassa fever virus, an approach that could lead to a superior alternative to highly toxic, non-FDA approved, and not readily available nucleotide analog inhibitors of replication. Zalgen’s mission is aided by its patented CHOLCelect mammalian expression platform for production of biological therapeutic molecules, with reduced development and manufacturing costs and enhanced regulatory compliance. Zalgen is also actively engaged in the development of novel human stem cell-based therapeutic platforms that could potentiate transformative medical applications for a broad array of human diseases.